A randomized controlled study was conducted to examine the plasma VEGF levels in 30 patients with DME and 30 patients with exudative ARMD before and up to one month after receiving a single intravitreal injection of bevacizumab, ranibizumab, or pegaptanib. The gene discussed is VEGFA; the disease is age-related macular degeneration.